Age-related macular degeneration (AMD) is a disease that occurs in the macula of the retina at the bottom of the eye, and is known as the “blindness killer”. However, due to the lack of awareness of the disease, some elderly people who suffer from it often think that it is caused by old eyes, resulting in delayed treatment and eventual blindness. The exact cause of AMD has not been determined and may be related to genetics, smoking, chronic photodamage, nutritional disorders, poisoning, and systemic diseases, or it may be the result of a combination of factors. The disease is an aging change of the macular structure, manifested by different degrees of degeneration, hyperplasia or atrophy. According to the fundus manifestation, it can be clinically divided into dry type and wet type. Dry type has no hemorrhage in the fundus and slow vision loss. In the wet type, neovascularization grows in the fundus, causing hemorrhage, which eventually leads to patch formation and severe vision loss. Because the cause of this disease is still unclear, there is no effective treatment or radical preventive measures available. Although some studies have shown that certain vitamins and minerals can help prevent the development or progression of dry AMD, it is too early to determine if they are effective, and it is not clear if they cause damage. Patients who take cholesterol-lowering medications and have a diet rich in leafy vegetables and nuts may have a slower progression of the disease. Some patients with wet AMD can be treated with thermal laser surgery, in which the damage is prevented from progressing by cauterizing the retina. Another possible treatment is photodynamic therapy (PDT) with the application of vetiprofen (Visudyne), which precisely targets blood vessels and causes less damage to the retina than thermal laser surgery. Currently, Avastin, a new drug approved by the FDA to inhibit angiogenesis and act as an anti-cancer agent, is highly effective in the treatment of neovascular and exudative lesions in the eye, and is particularly suitable for the treatment of wet AMD. Intravitreal injections of Avastin can significantly improve vision, induce neovascularization and reduce hemorrhage, and are inexpensive at about$17 to$50 per injection. Avastin has a long half-life, allowing for long intervals between injections, and has a promising short-term therapeutic effect with high safety and few toxic side effects.